Literature DB >> 7629423

Study of serum tumor markers CEA, CA 15.3 and CA 27.29 as diagnostic parameters in patients with breast carcinoma.

L Rodríguez de Paterna1, F Arnaiz, J Estenoz, B Ortuño, E Lanzós.   

Abstract

Serum levels of CEA, CA 15.3 and CA 27.29 were measured during the follow-up of 499 breast cancer patients. Studies included three different groups of women: 82 blood donors free of disease, 42 patients with non-malignant breast diseases and 499 breast cancer patients. After the determination of cut-off values, serum levels of tumor markers did not show significant elevations in benign breast diseases. On the basis of our results CA 15.3 (sensitivity = 57%; accuracy = 87%) was the most effective marker, CA 27.29 (sensitivity = 62%; accuracy = 83%) was the most sensitive and CEA (sensitivity = 45%; accuracy = 81%) was the least sensitive and effective marker. The combined use of markers was evaluated by step-wise logistic regression analysis. The regression coefficients showed that CA 15.3 (coeff. = 2.97) and CA 27.29 (coeff. = 1.46) were suitable for the detection of possible metastases during follow-up. Finally, we studied the relationship between pT, pN, pM and circulating levels of CA 15.3 and CA 27.29.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7629423     DOI: 10.1177/172460089501000105

Source DB:  PubMed          Journal:  Int J Biol Markers        ISSN: 0393-6155            Impact factor:   3.248


  2 in total

Review 1.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

2.  A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers.

Authors:  Rosina E Smith; Pablo Lespi; María Di Luca; Claudia Bustos; Fernando A Marra; María J T de Alaniz; Carlos A Marra
Journal:  Lipids       Date:  2007-11-29       Impact factor: 1.880

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.